Results 131 to 140 of about 9,532 (171)

Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti- CD38 monoclonal antibodies: outcomes from a real-world experience. [PDF]

Haematologica
Liberatore C, Ferretti VV, Tacchetti P, Conticello C, Barila G, Antonioli E, Belotti A, Cafro AM, Paris L, Bongarzoni V, Gentile M, Da Via M, Gamberi B, Pezzatti S, Ciambelli F, Garzia M, Annibali O, Fazio F, Antolino G, More S, Sgherza N, Farina F, Citro A, Steffanoni P, Del Fabro V, Cartia CS, Fioritoni F, Mancuso K, Attucci I, Pioltelli ML, Puppi M, Terlizzi S, Lisi C, Palumbo M, Offidani M, Petrucci MT, Mangiacavalli S.   +36 more
europepmc   +1 more source

Chemical tools for BAZ2A/B biology: discovery of dual and BAZ2B-selective PROTAC degraders. [PDF]

RSC Med Chem
Cheng-Sánchez I, Gosselé KA, Palaferri L, Krummhaar M, Laul E, Ciulli A, Nevado C.   +6 more
europepmc   +1 more source

Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation. [PDF]

Front Immunol
Adrados A, Pérez-Fernández J, García-Vicente R, Garrote-de-Barros A, Martinez-Lopez J, Linares M, Hernández-Sánchez M.   +6 more
europepmc   +1 more source

Li S, Pal R, Monaghan SA, et al. IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 2011;117(19):5157-5165.

Blood
europepmc   +1 more source

Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection.

Acta Haematol
Vikkula J, Remes K, Laatikainen O, Utriainen M, Tikka S, Lievonen J.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pomalidomide

Reactions Weekly, 2018
Pomalidomide (originally CC-4047 or 3-amino-thalidomide) is a derivative of thalidomide that is antiangiogenic and also acts as immunomodulatory. Pomalidomide, the recent immunomodulatory agent (IMiD), has shown substantial in vitro antiproliferative and proapoptotic effects.
Engelhardt, Monika, Ajayi, Stefanie, Reinhardt, Heike, Müller, Stefan Jürgen, Dold, Sandra Maria, Wäsch, Ralph   +5 more
  +11 more sources

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Lancet, The, 2019
BACKGROUND: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action.
Roman Hajek, Ian Kerridge, Athanasios Dimopoulos   +2 more
exaly   +5 more sources